Across TCGA pan-cancer cohorts, C11orf21 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C11orf21 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher C11orf21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C11orf21 expression acts as an unfavorable survival marker.
COAD and BRCA are the cancer types where C11orf21 Mutation most reproducibly stratifies survival.